Tumor-induced immune dysfunction

Cancer Immunology Immunotherapy

Volumn 48, Issue 7, 1999, Pages 353-362

  Kiessling, Rolf ^a   Wasserman, Ken ^b   Horiguchi, Shigetoshi ^a   Kono, Koji ^c   Sjöberg, Jan ^a   Pisa, Pavel ^a   Petersson, Max ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Cancer; CTL; Immunosuppression; NK cells; Tolerance; Zeta chains

Indexed keywords

CANCER; CELL ACTIVITY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; LEPROSY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TUMOR IMMUNOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; INFLAMMATION; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032843875     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050586     Document Type: Conference Paper

References (91)

1. Afeltra A, Galeazzi M, Ferri GM, Amoroso A, De Pita O, Porzio F, Bonomo L (1993) Expression of CD69 antigen on synovial fluid T cells in patients with rheumatoid arthritis and other chronic synovitis. Ann Rheum Dis 52:457
2. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM (1993) T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 53:1380
3. Anderson P, Caligiuri M, O'Brien C, Manley T, Ritz J, Schlossman SF (1990) Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci USA 87:2274
4. Aoe T, Okamoto Y, Saito T (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881
5. Ayroldi E, Migliorati G, Cannarile L, Moraca R, Delfino DV, Riccardi C (1997) CD2 rescues T cells from T-cell receptor/CD3 apoptosis: a role for the Fas/Fas-L system. Blood 89:3717
6. Bartik MM, Welker D, Kay NE (1998) Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 25:27
7. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F (1998) The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160:5669
8. Bingisser RM, Tilbrook PA, Holt PG, Kees UR (1998) Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 160:5729
9. Bosworth JL, Ghossein NA, Brooks TL (1975) Delayed hypersensitivity in patients treated by curative radiotherapy. Its relation to tumor response and short-term survival. Cancer 36:353
10. Buggins AG, Hirst WJ, Pagliuca A, Mufti GJ (1998) Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol 100:784
11. Choi SH, Chung EJ, Whang DY, Lee SS, Jang YS, Kim CW (1998) Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients. Cancer Immunol Immunother 45:299
12. Correa MR, Ochoa AC, Ghosh P, Mizoguchi H, Harvey L, Longo DL (1997) Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J Immunol 158:5292
13. Corsi MM, Maes HH, Wasserman K, Fulgenzi A, Gaja G, Ferrero ME (1998) Protection by L-oxothiazolidine-carboxylic acid of hydrogen peroxide-induced CD3zeta and CD16zeta chain down-regulation in human peripheral blood lymphocytes and lymphokine-activated killer cells. Biochem Pharmacol 56:657
14. Cunningham TJ, Daut D, Wolfgang PE, Mellyn M, Maciolek S, Sponzo RW, Horton J (1976) A correlation of DNCB-induced delayed cutaneous hypersensitivity reactions and the course of disease in patients with recurrent breast cancer. Cancer 37:1696
15. Dominioni L, Dionigi R, Dionigi P, Nazari S, Fossati GS, Prati U, Tibaldeschi C, Pavesi F (1981) Evaluation of possible causes of delayed hypersensitivity impairment in cancer patients. J Parenteral Enteral Nutr 5:300
16. Duke O, Panayi GS, Janossy G, Poulter LW, Tidman N (1983) Analysis of T cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies. Ann Rheum Dis 42:357
17. Elliott LH, Brooks WH, Roszrman TL (1990) Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J Clin Invest 86:80
18. Elsasser-Beile U, Kleist S von, Fischer R, Monting JS (1992) Impaired cytokine production in whole blood cell cultures from patients with colorectal carcinomas as compared to benign colorectal tumors and controls. J Clin Lab Anal 6:311
19. Elsasser-Beile U, Kleist S. von, Fischer R, Martin M, Wetterauer U, Gallati H, Monting JS (1993) Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas. J Cancer Res Clin Oncol 119:430
20. Elsasser-Beile U, Kleist S. von, Sauther W, Gallati H, Monting JS (1993) Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages. Br J Cancer 68:32
21. Elsasser-Beile U, Kolble N, Grussenmeyer T, Wetterauer U, Schultze-Seemann W (1998) Correlaticm of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid. Anticancer Res 18:1883
22. Firestein GS, Xu WD, Townsend K, Broide D, Alvaro-Gracia J, Glasebrook A, Zvaifler NJ (1988) Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 168:1573
23. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, Brautbar C, Battat S, Biberfeld P, Eckman M. et al (1995) Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86:1493
24. Ghosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, Longo DL, Rice NR, Komschlies KL (1994) Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 54:2969
25. Girolomoni G, Ricciardi-Castagnoli P (1997) Dendritic cells hold promise for immunotherapy. Immunol Today 18:102
26. Grever MR, Thompson VN, Balcerzak SP, Sagone AL Jr (1980) The effect of oxidant stress on human lymphocyte cytotoxicity. Blood 56:284
27. Gunji Y, Hori S, Aoe T, Asano T, Ochiai T, Isono K, Saito T (1994) High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn J Cancer Res 85:1189
28. Gutierrez-Steil C, Wrone-Smith T, Sun X, Krueger JG, Coven T, Nickoloff BJ (1998) Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). J Clin Invest 101:33
29. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363
30. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K (1996) Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 156:42
31. Hellstrand K, Hermodsson S, Brune M, Naredi P, Carneskog J, Mellqvist UH (1997) Histamine in cancer immunotherapy. Scand J Clin Lab Invest 57:193
32. Hellstrand K, Hermodsson S, Naredi P, Mellqvist UH, Brune M (1998) Histamine and cytokine therapy. Acta Oncol 37:347
33. Hemler ME, Glass D, Coblyn JS, Jacobson JG (1986) Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation. J Clin Invest 78:696
34. Hermans IF, Daish A, Yang J, Ritchie DS, Ronchese F (1998) Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res 58:3909
35. Herrath MG von, Evans CF, Horwitz MS, Oldstone MB (1996) Using transgenic mouse models to dissect the pathogenesis of virus-induced autoimmune disorders of the islets of Langerhans and the central nervous system. Immunol Rev 152:111
36. Hersh EM, Gutterman JU, Mavligit GM, Mountain CW, McBride CM, Brugess MA, Lurie PM, Zelen M, Takita H, Vincent RG (1976) Immunocompetence, immunodeficiency and prognosis in cancer. Ann NY Acad Sci 276:386
37. Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, Francke U, Reed JC, Kinoshita S, Nolan GP (1998) Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity 8:461
38. Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC, Kiessling R (1999) Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res (in press)
39. Kadish AS, Doyle AT, Steinhauer EH, Ghossein NA (1981) Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol 127:1817
40. Kingsley GH, Pitzalis C, Panayi GS (1987) Abnormal lymphocyte reactivity to self-major histocompatibility antigens in rheumatoid arthritis. J Rheumatol 14:667
41. Kono K, Ressing ME, Brandt RM, Melief CJ, Potkul RK, Andersson B, Petersson M, Kast MW, Kiessling R (1996) Decreased expression of signal transducing z chain on peripheral T cells and NK cells in patients with cervical cancer. Clin Cancer Res 2:1825
42. Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R (1996) Hydrogen peroxide secreted by tumor-derived macro-phages down-modulates signal-transducing zeta molecules and inhibits tumor-specifc T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 26:1308
43. Kopersztych S, Rezkallah MT, Miki SS, Naspitz CK, Mendes NF (1976) Cell-mediated immunity in patients with carcinoma: correlation between clinical stage and immunocompetence. Cancer 38:1149
44. Lai P, Rabinowich H, Crowley-Nowik PA, Bell MC, Mantovani G, Whiteside TL (1996) Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural-killer cells in patients with ovarian carcinoma. Clin Cancer Res 2:161
45. Leonard WJ, O'Shea JJ (1998) Jaks and STATs: biological implications. Annu Rev Immunol 16:293
46. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-associated macrophages. Immunol Today 13:265
47. Massaia M, Attisano C, Beggiato E, Bianchi A, Pileri A (1994) Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma. Br J Haematol 88:886
48. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765
49. Matsuda M, Ulfgren AK, Lenkei R, Petersson M, Ochoa AC, Lindblad S, Andersson P, Klareskog L, Kiessling R (1998) Decreased expression of signal-transducing CD3 zeta chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients. Scand J Immunol 47:254
50. Maurice MM, Lankester AC, Bezemer AC, Geertsma MF, Tak PP, Breedveld FC, Lier RA van, Verweij CL (1997) Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol 159:2973
51. Maurice MM, Nakamura H, Voort EA van der, Vliet AI van, Staal FJ, Tak PP, Breedveld FC, Verweij CL (1997) Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis. J Immunol 158:1458
52. Miescher S, Whiteside TL, Moretta L, Fliedner V von (1987) Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 138:4004
53. Mirza NM, Relias V, Yunis EJ, Pachas WN, Dasgupta JD (1993) Defective signal transduction via T-cell receptor-CD3 structure in T cells from rheumatoid arthritis patients. Hum Immunol 36:91
54. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL (1997) T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159:4415
55. Morris DL, Hersh EM, Hsi BP, Gutterman JU, Marshall MM, Mavligit GM (1979) Recall antigen delayed-type hypersensitivity skin testing in melanoma and acute leukemia patients and their associates. Cancer Res 39:219
56. Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961
57. Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ (1997) T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40:113
58. Nieland JD, Loviscek K, Kono K, Albain KS, McCall AR, Potkul RK, Fisher SG, Velders MP, Petersson M, Kiessling R, Kast WM (1998) PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. J Immunother 21:317
59. Nykanen P, Bergroth V, Raunio P, Nordstrom D, Konttinen YT (1986) Phenotypic characterization of 3H-thymidine incorporating cells in rheumatoid arthritis synovial membrane. Rheumatol Int 6:269
60. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H (1991) Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305
61. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T (1996) Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A 93:13119
62. Pawelec G, Zeuthen J, Kiessling R (1997) Escape from hostantitumor immunity. Crit Rev Oncog 8:111
63. Pericle F, Kirken RA, Bronte V, Sconocchia G, DaSilva L, Segal DM (1997) Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. J Immunol 159:2580
64. Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B, Kiessling R (1992) Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci USA 89:7708
65. Pope RM, McChesney L, Talal N, Fischbach M (1984) Characterization of the defective autologous mixed lymphocyte response in rheumatoid arthritis. Arthritis Rheum 27:1234
66. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4:627
67. Rabinowich H, Banks M, Reichert T, Logan TF, Kirkwood JM, Whiteside TL (1996) Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after therapy. Clin Cancer Res 2:1263
68. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 101:2579
69. Reichert TE, Day R, Wagner EM, Whiteside TL (1998) Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58:5344
70. Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier JP, Pfreundschuh M (1996) T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 88:236
71. Ressing ME, Driel WJ van, Celis E, Sette A, Brandt MP, Hartman M, Anholts JD, Schreuder GM, Harmsel WB ter, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJ (1996) Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 56:582
72. Reuben JM, Hersh EM (1984) Delayed hypersensitivity responses of cancer patients to recall antigens using a new "Multitest" applicator. Ann Allergy 53:390
73. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316:889
74. Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naeher H, Rammensee HG, Keilholz U (1997) Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 71:932
75. Sotomayor EM, Borrello I, Levitsky HI (1996) Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog 7:433
76. Staal FJ, Ela SW, Roederer M, Anderson MT, Herzenberg LA (1992) Glutathione deficiency and human immunodeficiency virus infection. Lancet 339:909
77. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H (1998) Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95:1178
78. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045
79. Takahashi H, Soderstrom K, Nilsson E, Kiessling R, Patarroyo M (1992) Integrins and other adhesion molecules on lymphocytes from synovial fluid and peripheral blood of rheumatoid arthritis patients. Eur J Immunol 22:2879
80. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, D'Enghien CD, Lee R, Debre B, Fridman WH (1995) Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 63:205
81. Trimble LA, Lieberman J (1998) Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood 91:585
82. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 187:2065
83. Wedelin C, Bjorkholm M, Holm G, Ogenstad S, Johansson B, Mellstedt H (1982) Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis. Br J Cancer 45:70
84. Wegener AM, Letourneur F, Hoeveler A, Brocker T, Luton F, Malissen B (1992) The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell 68:83
85. Wesch D, Marx S, Kabelitz D (1998) Monocyte-dependent death of freshly isolated T lymphocytes: induction by phorbolester and mitogens and differential effects of catalase. J Immunol 161:1248
86. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H (1997) Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 186:229
87. Wu MX, Daley JF, Rasmussen RA, Schlossman SF (1995) Monocytes are required to prime peripheral blood T cells to undergo apoptosis. Proc Natl Acad Sci USA 92:1525
88. Yamauchi A, Taga K, Mostowski HS, Bloom ET (1996) Target cell-induced apoptosis of interleukin-2 activated human natural killer cells: roles of cell surface molecules and intracellular events. Blood 87:5127
89. Zea AH, Curti BD, Londo DL, Alvord WG, Strobi SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers CG, Urba WJ, Ochoa AC (1995) Alterations in T cell receptor and signal-transduction molecules in melanoma patients. Clin Cancer Res 1:1327
90. Zea AH, Ochoa MT, Ghosh P, Longo DL, Alvord WG, Valderrama L, Falabella R, Harvey LK, Saravia N, Moreno LH, Ochoa AC (1998) Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun 66:499
91. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS (1997) Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 90:1952